Early research (Phase 1)Study completedNCT02044120
What this trial is testing
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma
Who this might be right for
Ewing Sarcoma
Sarcoma Alliance for Research through Collaboration 34